The highly potent and selective third generation RXR agonist compound IRX4204 is a potential treatment for normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD)
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., Federation of American Societies for Experimental Biology, July 2024
IRX4204 A Phase II Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Parkinson’s Disease
Martin E. Sanders, M.D., Sichuan Provincial Neuroscience Society, 2023
IRX4204 – A Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Psoriasis and other Autoimmune Skin Diseases
Martin E. Sanders, M.D.
IRX4204 – A Phase II Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Neurodegenerative and Autoimmune Diseases
Martin E. Sanders, M.D., BIO International Convention, 2023
Io Therapeutics Phase II Clinical Stage and Preclinical Retinoid Compounds for Treatment of Cancers
Martin E. Sanders, M.D., BIO International Convention, 2023